文献速递类风湿关节炎

扩展心血管风险预测评分在瑞典类风湿关节炎队列中的外部验证

Performance of the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis in a geographically distant National Register-based cohort: an external validation.
PubMed 文献 · RMD Open · 2018-12-16

本研究基于瑞典风湿病质量登记的三个大型部分重叠类风湿关节炎(RA)队列,对源自美国数据的扩展心血管风险预测评分(ERS-RA)进行外部验证。结果显示ERS-RA的C指数为0.75至0.78,在低中风险区间校准良好,但在高风险组及缺乏吸烟数据时低估10年心血管风险,提示其可作为临床风险分层工具。

要点

  • ERS-RA在瑞典RA队列中区分度良好,C指数0.75-0.78。
  • 观察10年心血管风险≤10%时预测与观察风险吻合良好。
  • 高风险组及无吸烟数据时ERS-RA低估风险,分别可达3.3%。

核心结论

  • 在未选择的瑞典RA人群中ERS-RA整体表现良好,但高风险组和无吸烟数据时10年心血管风险被低估。
  • ERS-RA可考虑作为临床风湿病实践中靶向预防干预的风险分层工具。

研究设计与样本

  • 研究基于瑞典风湿病质量登记的三个大型、部分重叠的RA队列进行外部验证,其中两个队列有吸烟信息,两个队列中位随访接近10年。
  • 采用Kaplan-Meier法评估10年首次心血管事件发生率,以C指数和观察风险与预测风险比较评估ERS-RA性能。

主要发现

  • ERS-RA的C指数在三个RA队列中为0.75至0.78。
  • 在观察10年心血管风险≤10%的个体中,预测风险与观察风险对应良好;在观察风险更高的个体中风险被低估。
  • 无吸烟数据时ERS-RA低估心血管风险3.3%,而有吸烟数据的队列校准差异在1%以内(0.06%和0.7%)。
  • 在临床相关风险区间(<5%、5.0%-<7.5%、7.5%-<10%)ERS-RA表现良好。

关键数值与推荐

  • C指数范围0.75-0.78。
  • 无吸烟数据时风险低估3.3%;有吸烟数据时校准差异0.06%和0.7%。
  • 临床相关风险区间:<5%、5.0%-<7.5%、7.5%-<10%。

临床怎么用

  • ERS-RA可用于RA患者的心血管风险分层,辅助靶向预防干预决策。
  • 在高风险患者或缺乏吸烟数据时,需警惕ERS-RA对10年心血管风险的低估。

局限性

  • 研究基于瑞典登记数据,外部推广性需进一步验证。
  • 部分队列缺乏吸烟数据,影响风险校准评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiovascular (CV) risk stratification for patients with rheumatoid arthritis (RA) should facilitate evidence-based management. Prior work has derived an internally validated a CV risk score, the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis (ERS-RA), using US data. The aim of this study was to perform an external validation among unselected patients with RA from Europe. METHODS: Three large, partially overlapping, cohorts of patients with RA from the Swedish Rheumatology Quality register were identified for external validation, two with information on smoking and two with close to 10 years of median follow-up. The 10 -year rate of first CV events was assessed using the Kaplan-Meier method. The performance of ERS-RA was assessed using C-index and comparisons of observed versus predicted risks. RESULTS: The C-index for ERS-RA varied across the three RA cohorts, from 0.75 to 0.78. Predicted risks corresponded well to observed risks among individuals with ≤10 % observed 10- year CV risk, but underestimated risk in individuals with a higher observed risk. In the absence of data on smoking, ERS-RA underestimated the CV risk by 3.3%, whereas in the cohorts including data on smoking, the calibration was within 1% (0.06% and 0.7%). In the clinically relevant risk intervals (<5%, 5.0%-<7.5%, 7.5%-<10%), ERS-RA performed well. CONCLUSIONS: In an unselected Swedish population with RA, ERS-RA performed well, although the 10-year CV risk was underestimated in high-risk groups and in the absence of data on smoking. ERS-RA could be considered as a risk stratification tool for targeted preventive interventions in clinical rheumatology practice.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Ljung L, Ueda P, Liao KP, et al. Performance of the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis in a geographically distant National Register-based cohort: an external validation. RMD Open. 2018. PMID: 30622736. doi:10.1136/rmdopen-2018-000771

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。